Bicycle Therapeutics logo

BCYC - Bicycle Therapeutics News Story

$14.15 0.7  5.1%

Last Trade - 06/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £208.2m
Enterprise Value £132.9m
Revenue £11.3m
Position in Universe 3189th / 6312

BUZZ-Bicycle Therapeutics shares ride higher on early-stage trial data

Mon 1st July, 2019 1:34pm
** Shares of drug developer  BCYC.O  rise 10% to $11.07
premarket    
    ** Says partner Oxurion's early-stage study in patients with
an eye condition brought on by diabetes recorded no drug-related
side effects or dose-limiting toxicities 
    ** Trial was testing the safety of a single injection of
experimental drug THR-149 in three doses in 12 subjects with
visual impairment due to diabetic macular edema  urn:newsml:reuters.com:*:nBw6ZWbwqa
    ** The results are evidence of the clinical potential of
BCYC's technology as its develops its cancer drug, co says 
    ** Up to Friday's close, stock had fallen 16% YTD

 (Reporting by Tamara Mathias in Bengaluru)
 ((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 1208; Reuters Messaging:
tamara.mathias.thomsonreuters.com@reuters.net))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.